| Stage | CAT | % of rev | ASTE | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $20.7B | 100.00% | $408M | 100.00% | CAT ×50.68 |
| Gross profit | $7.3B | 35.54% | $107M | 26.17% | CAT +9.4pp |
| Operating income | $4.2B | 20.38% | $20M | 5.00% | CAT +15.4pp |
| Pre-tax income | $4.2B | 20.40% | $15M | 3.68% | CAT +16.7pp |
| Net income | $3.3B | 15.89% | $11M | 2.57% | CAT +13.3pp |
| Stage | CAT | ASTE | Gap · A − B |
|---|---|---|---|
| Revenue | $20.7B100.00% | $408M100.00% | CAT ×50.68 |
| Gross profit | 35.54%$7.3B | 26.17%$107M | CAT +9.4pp |
| Operating income | 20.38%$4.2B | 5.00%$20M | CAT +15.4pp |
| Pre-tax income | 20.40%$4.2B | 3.68%$15M | CAT +16.7pp |
| Net income | 15.89%$3.3B | 2.57%$11M | CAT +13.3pp |
No disclosed counterparties: ASTE.
None